The Active Oxygen Species Assays market research report covers a worldwide outlook of the industry with specifically studying the manufacturers/ key market players. The historical, current, and forecast sales data provided in the report highlights the market's latest trends and future growth scope. The upcoming trends and anticipated risk factors of the market are also covered in the report giving the holistic prospective of the market. The segmentation by type and application is studied at the country level for the study period 2022 to 2028.
As the global economy mends, the 2021 growth of Active Oxygen Species Assays will have significant change from previous year. According to this latest study, the global Active Oxygen Species Assays market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Active Oxygen Species Assays market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Active Oxygen Species Assays market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Active Oxygen Species Assays market, reaching US$ million by the year 2028. As for the Europe Active Oxygen Species Assays landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Active Oxygen Species Assays players cover Abcam plc (U.K.), AMS Biotechnology (U.K.), BioVision, Inc. (U.S.), and Cell Biolabs, Inc. (U.S.), etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Active Oxygen Species Assays market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
- ELISA Technology
- Flow Cytometry Technology
- Chromatography Technology
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
- Pharmaceutical And Biotechnology Companies
- Academic Institution
- Clinical Laboratory
- Cosmetics Industry
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
- Abcam plc (U.K.)
- AMS Biotechnology (U.K.)
- BioVision, Inc. (U.S.)
- Cell Biolabs, Inc. (U.S.)
- Enzo Biochem (U.S.)
- Merck (U.S.)
- Oxford Biomedical Research (U.S.)
- QIAGEN N.V. (Netherlands)
- Promega Corporation (U.S.)
- Sigma-Aldrich Corporation (U.S.)
- Thermo Fisher Scientific (U.S.)